June 15, 2026
Trip or treatment?
Successful Psilocybin Treatment of Alzheimer
Magic mushrooms spark hope, side-eyes, and a full-blown comment war
TLDR: A case report says one woman with advanced Alzheimer’s showed temporary improvement after taking psilocybin mushrooms, raising eyebrows because there’s usually little hope of recovery at that stage. Commenters immediately split into two camps: hopeful risk-takers and skeptics calling it overhyped, flimsy, and way too early to celebrate.
A wild medical case report claiming temporary improvements in severe Alzheimer’s after psilocybin mushrooms has sent the internet straight into debate mode. The paper describes an elderly woman with advanced memory loss and major day-to-day impairment who reportedly became more talkative, more emotionally responsive, and more independent for a time after taking a large dose of psychedelic mushrooms. That’s the part social media grabbed and ran with. But in the comments, people were much less ready to call it a miracle.
The loudest reaction? “Slow down.” Skeptics were practically waving red flags in all caps: this was just one patient, not a full study, and critics pounced on everything from the diagnosis wording to the lack of a more controlled drug sample. One commenter summed up the mood with a savage checklist ending in, basically, “extraordinary claims need extraordinary evidence.” Others were even more blunt, calling the whole thing “witch doctor science” and gasping at the 5-gram dose, which many readers treated like the scientific equivalent of “you did WHAT?”
Still, not everyone was dunking on it. Some readers argued that, messy or not, this is exactly the kind of risky, uncomfortable research that could uncover something huge for families dealing with Alzheimer’s. Another twist: one commenter said the case had already popped up on Joe Rogan, which only added more “is this groundbreaking or just internet rocket fuel?” energy. The result: a classic comment-section cage match between desperate hope, scientific skepticism, and psychedelic hype.
Key Points
- •The article reports a single case involving an octogenarian woman with advanced Alzheimer’s disease and severe long-term functional impairment.
- •The patient received 5 g of orally administered psilocybin-containing mushrooms identified as the Enigma strain.
- •The acute post-administration period included autonomic activation, suspected hyperthermia, profuse sweating, and a prolonged deep sleep-like state.
- •Roughly 19 hours after administration, the report says spontaneous autobiographical speech appeared, followed by improvements in continence, mobility, communication, and social engagement over days and weeks.
- •The article concludes that the case does not demonstrate reversal of Alzheimer’s disease, but may indicate transient access to residual functional capacity under specific neuromodulatory conditions.